Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib + sintilimab + HAIC
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous, Intra-arterial
01
Overview
This is a combination therapy consisting of donafenib, sintilimab, and hepatic artery infusion chemotherapy (HAIC). Donafenib is an oral small molecule multikinase inhibitor targeting several kinases involved in tumor growth and angiogenesis. Sintilimab is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting programmed cell death protein 1 (PD-1), thereby enhancing the immune system's ability to attack cancer cells. HAIC involves the direct infusion of chemotherapeutic agents into the hepatic artery to increase drug concentration at liver tumors while minimizing systemic exposure. This combination has been investigated primarily for advanced or unresectable hepatocellular carcinoma (HCC), particularly in patients with high-risk features such as portal vein tumor thrombus[1][2][4][5].
- Other names
- HAIC with Sintilimab and DonafenibDonafenib + Sintilimab + Hepatic Arterial Infusion Chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on donafenib + sintilimab + HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib + sintilimab + HAIC.